Welcome to our dedicated page for 180 Life Sciences news (Ticker: ATNF), a resource for investors and traders seeking the latest updates and insights on 180 Life Sciences stock.
The ATNF news page on Stock Titan provides an archive of announcements and press releases related to 180 Life Sciences Corp. and its transformation into the ETHZilla brand. Readers can follow how the company evolved from an innovative biotechnology business into a firm focused on the global iGaming sector and, more recently, on an Ethereum (ETH) treasury strategy.
Company news covers several distinct themes. First, there are updates on private placements and financing transactions, including a large PIPE offering and a convertible note issuance that the company has stated are intended to fund the rapid accumulation of Ether and related yield-bearing assets. These items often detail the structure of the financings and the company’s intended use of proceeds, such as ETH purchases, support for iGaming operations, and efforts to monetize legacy biotech intellectual property.
Second, the news flow includes treasury and ETH holdings updates, where the company reports the amount of ETH it holds, the approximate value of those holdings, and the role of Electric Capital as external asset manager for its on-chain yield generation program. These releases provide insight into how the ETH treasury strategy is being implemented over time.
Third, investors can review corporate strategy and governance announcements, including the planned rebranding to ETHZilla Corporation, changes in ticker symbols, board appointments, and steps taken to regain or maintain compliance with Nasdaq listing requirements. Additional releases describe the company’s pivot into iGaming, its proprietary Technology Gaming Platform, and ongoing development of gaming initiatives.
Finally, the archive includes biotechnology IP and patent updates, such as notices of allowance and granted patents related to post-operative cognitive decline, neuroinflammation, and fibrotic disorders. Together, these news items document the company’s multi-stage evolution and provide context for both its historical biotech activities and its current focus on digital assets and gaming.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
180 Life Sciences Corp. (NASDAQ: ATNF) announced the closing of its registered direct offering, selling 1,570,680 shares of common stock and warrants, generating approximately $3 million in gross proceeds. The shares were priced at $1.91 each, with warrants allowing purchase at $1.78. The net proceeds will fund research and development expenses, including a marketing authorization application.
A.G.P./Alliance Global Partners acted as the placement agent. The offering is based on an effective shelf registration statement with the SEC filed previously. Additionally, existing warrants for 2,878,032 shares will be amended to lower the exercise price to $1.78 and extend the expiration.